Trastuzumab Side Effects
It is possible that some side effects of trastuzumab may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
For the Consumer
Applies to trastuzumab: intravenous powder for solution
As well as its needed effects, trastuzumab may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking trastuzumab, check with your doctor or nurse immediately:More common
- fever or chills
- muscle aches
- nausea or vomiting
- shortness of breath
- skin rash
- sore throat
- stuffy or runny nose
- unusual tiredness or weakness
- Bloody nose
- difficult or labored breathing
- ear congestion or pain
- fast or irregular heartbeat
- general feeling of discomfort or illness
- head congestion
- hoarseness or other voice changes
- increased cough
- joint pain
- loss of appetite
- nasal congestion
- pain or tenderness around the eyes and cheekbones
- swelling of the feet or lower legs
- tightness in the chest
- trouble with sleeping
- Blue lips and fingernails
- blurred vision
- chest pain
- cough or hoarseness, accompanied by fever or chills
- faintness or lightheadedness when getting up suddenly from a lying or sitting position suddenly
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, feet, or sex organs
- lower back or side pain, accompanied by fever or chills
- painful or difficult urination, accompanied by fever or chills
- pale skin
- redness of the skin
- trouble with breathing
- Black, tarry stools
- bloody or cloudy urine
- sores, ulcers, or white spots in the mouth
- unusual bleeding or bruising
- weight gain
Some trastuzumab side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:More common
- Numbness or tingling of the hands or feet
For Healthcare Professionals
Applies to trastuzumab: intravenous powder for injection
Cardiovascular side effects including congestive heart failure (7%), tachycardia (5%), angioedema, asymptomatic drops in LVEF, and elevated blood pressure have been reported. Trastuzumab has also been associated with an increased risk of asymptomatic decreases in ejection fraction and a case report of peripheral vascular toxicity.
A randomized, Phase III trial that was conducted in 2043 women with operable, HER2 overexpressing breast cancer demonstrated a significant increase in cardiotoxicity in patients who were randomized to the trastuzumab-containing arm as compared to patients who received chemotherapy alone. Preliminary analysis of safety data revealed a statistically significant increase in the 3 year cumulative incidence of New York Heart Association Class III and IV congestive heart failure and cardiac death observed in patients who received the trastuzumab-containing regimen (4.1%) compared with control (0.8%). There were no cardiac deaths observed in patients who received the trastuzumab-containing regimen and one cardiac death was observed in the control arm. Final analysis of the cardiac safety data collected in these studies is ongoing.
The infusion of trastuzumab should be interrupted for patients experiencing clinically significant hypotension. Discontinuation of therapy should be strongly considered for patients who develop angioedema.
Trastuzumab is associated with an increased risk of cardiac dysfunction which is greatest in patients receiving concurrent anthracyclines.
General side effects including pain (47%), asthenia (42%), fever (36%), chills (32%), headache (26%), abdominal pain (22%), back pain (22%), infection (20%), flu syndrome (10%), and accidental injury (6%) have been reported.
Gastrointestinal side effects including nausea (33%), diarrhea (25%), vomiting (23%), anorexia (14%), and nausea with vomiting (8%) have been reported.
Adverse reactions requiring interruption or discontinuation of trastuzumab treatment include pulmonary toxicity. The infusion of trastuzumab should be interrupted for patients experiencing dyspnea. Discontinuation of therapy should be strongly considered for patients who develop acute respiratory distress syndrome.
Respiratory side effects including adult respiratory distress syndrome have been reported. Fifteen patients have been reported to have experienced pulmonary and other adverse events which lead to fatalities. Increased cough (26%), dyspnea (22%), rhinitis (14%), pharyngitis (12%), and sinusitis (9%) have also been reported.
Patients should be monitored closely until signs and symptoms of the hypersensitivity reaction completely resolve. Discontinuation of therapy should be strongly considered for patients who develop anaphylaxis.
Hypersensitivity side effects including fatal anaphylaxis have been reported. There have been sixty-two postmarketing reports of serious adverse events related to the use of trastuzumab. These events have been hypersensitivity, infusion, and/or pulmonary reactions.
Local side effects including infusion reactions (some of which had fatal outcomes) have been reported.
Dermatologic side effects including rash (18%), herpes simplex (2%), and acne (2%) have been reported.
Nervous system side effects including insomnia (14%), dizziness (13%), paresthesia (9%), depression (6%), peripheral neuritis (2%), and neuropathy (1%) have been reported.
Metabolic side effects including peripheral edema (10%) and edema (8%) have been reported.
Musculoskeletal side effects including bone pain (7%) and arthralgia (6%) have been reported.
Genitourinary side effects including urinary tract infection (5%) have been reported.
Hematologic side effects including anemia (4%), leukopenia (3%), neutropenia, and febrile neutropenia have been reported. A case of thrombocytopenia has also been reported.
Deaths due to sepsis in patients with severe neutropenia have been reported in patients receiving trastuzumab and myelosuppressive chemotherapy.
Oncologic side effects including central nervous system metastases have been reported.
Hepatic side effects including a case of hepatotoxicity have been reported.
More about trastuzumab
- Other brands: Herceptin
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.